HMGN2P35

Across TCGA pan-cancer cohorts, HMGN2P35 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated HMGN2P35 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher HMGN2P35 RNA is associated with better overall survival. In most high-consensus cancer types, elevated HMGN2P35 expression acts as an unfavorable survival marker, although some lineages such as PAAD and CESC show a favorable association.

PAAD, ESCA, and CESC are the cancer types where HMGN2P35 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.740	0.406	<.001	43	view →
ESCA	OS	Median	All	0.474	1.000	.021	32	view →
CESC	OS	Median	All	0.929	0.819	.005	26	view →
THYM	OS	Tertile	IV	0.294	1.000	.025	18	view →
TGCT	OS	Tertile	All	0.930	1.000	.019	10	view →
BLCA	OS	Tertile	IV	0.382	0.636	.038	9	view →
SKCM	OS	Quartile	All	0.873	0.743	.024	9	view →
COAD	OS	Median	IV	0.262	0.641	.021	9	view →
LIHC	DFS	Tertile	III,IV	0.162	0.353	.045	9	view →
DLBC	OS	Median	All	1.000	0.585	.027	5	view →
GBM	DFS	Tertile	All	0.265	0.185	.036	3	view →
CHOL	OS	Tertile	All	1.000	0.673	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

HMGN2P35–PAAD (OS)

Open the PAAD breakdown →